Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ PASC -14% Improvement Relative Risk c19early.org/pl Durstenfeld et al. Paxlovid for COVID-19 LONG COVID Does paxlovid reduce the risk of Long COVID (PASC)? Retrospective 4,684 patients in the USA No significant difference in PASC Durstenfeld et al., medRxiv, doi:10.1101/2023.03.02.23286730 Favors paxlovid Favors control
Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of Non-Hospitalized Individuals Experiencing Breakthrough SARS-CoV-2 Infection in the Omicron Era
Durstenfeld et al., medRxiv, doi:10.1101/2023.03.02.23286730
Durstenfeld et al., Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of.., medRxiv, doi:10.1101/2023.03.02.23286730
Mar 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 4,684 COVID+ patients mostly in the USA, 988 treated with paxlovid, showing higher odds of long COVID with treatment, without statistical significance.
[Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
risk of PASC, 14.3% higher, RR 1.14, p = 0.40, treatment 57 of 353 (16.1%), control 176 of 1,258 (14.0%), odds ratio converted to relative risk, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Durstenfeld et al., 5 Mar 2023, retrospective, USA, peer-reviewed, 13 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit